利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.04 秒)

    Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
    2.
    发明授权
    Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions 有权
    用于通过非同源转换区产生人抗体特异性同种型的转基因动物

    公开(公告)号：US06833268B1

    公开(公告)日：2004-12-21

    申请号：US09329582

    申请日：1999-06-10

    申请人： Larry L. Green ,  Vladimir E. Ivanov ,  C. Geoffrey Davis

    发明人： Larry L. Green ,  Vladimir E. Ivanov ,  C. Geoffrey Davis

    IPC分类号： C12N1563

    CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/241 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/52 ,  C12N5/0606 ,  C12N2510/00 ,  C12N2800/30 ,  C12N2830/00

    摘要： The present invention provides fully human antibodies in a transgenic animal of a desired isotype in response to immunization with any virtually any desired antigen. The human immunoglobulin heavy chain transgene in the foregoing animals comprises a human constant region gene segment comprising exons encoding the desired heavy chain isotype, operably linked to switch segments from a constant region of a different heavy chain isotype, i.e., a non-cognate switch region. Said additional constant region segment comprises a switch region and human constant region coding segment, wherein the constant region coding segment is operably linked to a switch region that it is not normally associated with, i.e., a non-cognate switch region. In the transgenes of the invention, the non-cognate switch region may be a switch region from a different species than the constant region coding segment. The switch region and membrane exons of the invention may comprise a human gamma-2 constant region and the secreted constant region exons are from a human gamma-1 or a human gamma-4 constant region.

    摘要翻译： 本发明在任何实际上任何所需抗原的免疫响应中，在所需同种型的转基因动物中提供完全人抗体。 前述动物中的人免疫球蛋白重链转基因包含人恒定区基因片段，其包含编码所需重链同种型的外显子，其可操作地连接于不同重链同种型的恒定区切换片段，即非同源转换区 。 所述附加恒定区段包括开关区域和人类恒定区域编码区段，其中恒定区域编码段可操作地连接到其通常不与非同源开关区域相关联的开关区域。 在本发明的转基因中，非同源开关区可以是来自与恒定区编码区不同的种的开关区。 本发明的切换区和膜外显子可以包含人γ-2恒定区，分泌的恒定区外显子来自人γ-1或人γ-4恒定区。

    Antibodies to c-Met
    3.
    发明授权
    Antibodies to c-Met 有权
    c-Met的抗体

    公开(公告)号：US08163280B2

    公开(公告)日：2012-04-24

    申请号：US12321963

    申请日：2009-01-26

    申请人： Neil R. Michaud ,  Shama Kajiji ,  Gary Borzillo ,  Vahe Bedian ,  Kevin Coleman ,  Larry L. Green ,  Xiao-Chi Jia

    发明人： Neil R. Michaud ,  Shama Kajiji ,  Gary Borzillo ,  Vahe Bedian ,  Kevin Coleman ,  Larry L. Green ,  Xiao-Chi Jia

    IPC分类号： A61K39/395

    CPC分类号： A61K39/39558 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/3076 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

    摘要翻译： 本发明涉及特异性结合c-Met，优选人c-Met的人抗体及其抗原结合部分的抗体，其功能是抑制c-Met。 本发明还涉及人抗c-Met抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗c-Met抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗c-Met抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗c-Met抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。

    Antibodies to MAdCAM
    4.
    发明授权
    Antibodies to MAdCAM 有权
    MAdCAM的抗体

    公开(公告)号：US07932372B2

    公开(公告)日：2011-04-26

    申请号：US11484247

    申请日：2006-07-10

    申请人： Nicholas Pullen ,  Elizabeth Molloy ,  Sirid-Aimée Kellermann ,  Larry L. Green ,  Mary Haak-Frendscho

    发明人： Nicholas Pullen ,  Elizabeth Molloy ,  Sirid-Aimée Kellermann ,  Larry L. Green ,  Mary Haak-Frendscho

    IPC分类号： C12N15/13 ,  C12N5/00 ,  C12N1/21 ,  C12N15/63

    CPC分类号： C07K16/2803 ,  A61K2039/505 ,  C07K14/70503 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56972 ,  G01N33/6854 ,  G01N2333/70503 ,  G01N2333/70546

    摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.

    摘要翻译： 本发明涉及特异性结合MAdCAM，优选人MAdCAM的人抗体及其抗原结合部分的抗体，其功能是抑制MAdCAM。 本发明还涉及人抗MAdCAM抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗MAdCAM抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗MAdCAM抗体的方法，包含这些抗体的组合物和使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗MAdCAM抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。

    Antibodies to c-Met
    6.
    发明申请
    Antibodies to c-Met 有权
    c-Met的抗体

    公开(公告)号：US20100040629A1

    公开(公告)日：2010-02-18

    申请号：US12321963

    申请日：2009-01-26

    申请人： Neil R. Michaud ,  Shama Kajiji ,  Gary Borzillo ,  Vahe Bedian ,  Kevin Coleman ,  Larry L. Green ,  Xiao-Chi Jia

    发明人： Neil R. Michaud ,  Shama Kajiji ,  Gary Borzillo ,  Vahe Bedian ,  Kevin Coleman ,  Larry L. Green ,  Xiao-Chi Jia

    IPC分类号： A61K39/395

    CPC分类号： A61K39/39558 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/3076 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

    摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit c-Met. The invention also relates to human anti-c-Met antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-c-Met antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-c-Met antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-c-Met antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.

    摘要翻译： 本发明涉及特异性结合c-Met，优选人c-Met的人抗体及其抗原结合部分的抗体，其功能是抑制c-Met。 本发明还涉及人抗c-Met抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗c-Met抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗c-Met抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗c-Met抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。

    Antibodies to CCR2
    8.
    发明授权
    Antibodies to CCR2 有权
    CCR2抗体

    公开(公告)号：US08710191B2

    公开(公告)日：2014-04-29

    申请号：US13059702

    申请日：2009-08-17

    申请人： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina Liang

    发明人： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina Liang

    IPC分类号： C07K16/28 ,  C07K16/00

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

    摘要： Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, specifically human CCR2, and that may function to inhibit CCR2. Anti-CCR2 antibodies include those which bind to the first and/or second extracellular loops of CCR2. Also provided are human anti-CCR2 antibodies and antigen-binding portions thereof. Isolated heavy and light chain immunoglobulins derived from human anti-CCR2 antibodies and nucleic acid molecules encoding such immunoglobulins are provided. Methods of making human anti-CCR2 antibodies or antigen-binding portions, compositions comprising these antibodies or antigen-binding portions, methods of using the antibodies and antigen-binding portions, and compositions for diagnosis and treatment are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CCR2 antibodies or antigen binding portions thereof.

    摘要翻译： 提供了抗体，其包括特异性结合CCR2的人抗体及其抗原结合部分，特别是人CCR2，并且其可能起抑制CCR2的作用。 抗CCR2抗体包括结合CCR2的第一和/或第二细胞外环的那些抗体。 还提供了人抗CCR2抗体及其抗原结合部分。 提供衍生自人抗CCR2抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 提供制备人抗CCR2抗体或抗原结合部分的方法，包含这些抗体或抗原结合部分的组合物，使用抗体和抗原结合部分的方法，以及用于诊断和治疗的组合物。 还提供了使用编码包含人抗CCR2抗体或其抗原结合部分的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。

    Reducing the risk of human anti-human antibodies through V gene manipulation
    9.
    发明授权
    Reducing the risk of human anti-human antibodies through V gene manipulation 失效
    通过V基因操作降低人抗人抗体的风险

    公开(公告)号：US08198508B2

    公开(公告)日：2012-06-12

    申请号：US12577696

    申请日：2009-10-12

    申请人： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    发明人： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    IPC分类号： A01K67/00 ,  A01K67/027 ,  A61K49/00

    CPC分类号： G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    摘要： The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. Some embodiments herein are directed to transgenic mouse embodiments relevant for HAHA responses.

    摘要翻译： 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。 本文的一些实施方案涉及与HAHA反应相关的转基因小鼠实施方案。